专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明公开

EP2059587A4 LACCASES FOR PULP BIO-BLEACHING 有权
标题翻译：纸浆生物漂白用胶条
公开(公告)号：EP2059587A4
公开(公告)日：2009-12-16
申请号：EP07837576
申请日：2007-08-31
申请人： VERENIUM CORP , BASF SE
发明人： KEROVUO JANNE SAMULI , HAREMZA SYLKE , KOCH OLIVER , HABICHER TILO , ROBERTSON DAN , DESANTIS GRACE , MCCANN RYAN , LUGINBUHL PETER
IPC分类号： C12N9/02 , A61K38/44 , C07H21/04 , C07K1/00 , C07K16/00 , C12N1/20 , C12N15/00 , C12P21/04 , C12P21/06 , C12Q1/00 , C12Q1/34 , C12Q1/68
CPC分类号： C12N9/0061 , C12N15/09 , C12P5/00 , C12P7/00 , C12P19/00 , C12Y110/03002 , D21C5/005 , D21C9/005 , D21C9/1063

92. 发明授权

EP1558729B1 RAPIDLY DEGRADED REPORTER FUSION PROTEINS 有权
标题翻译： FAST开采报导融合蛋白
公开(公告)号：EP1558729B1
公开(公告)日：2009-12-09
申请号：EP03754599.3
申请日：2003-09-16
申请人： PROMEGA CORPORATION
发明人： ZDANOVSKY, Alexey , ZDANOVSKAIA, Marina , MA, Dongping , WOOD, Keith V. , ALMOND, Brian D. , WOOD, Monika G.
IPC分类号： C12N9/14 , C12N1/20 , C12N15/00 , C12Q1/00 , C12Q1/34 , C12Q1/68 , C12P21/06 , C12P21/04 , A61K38/44 , C07H21/04 , C07K1/00 , C12N9/62
CPC分类号： C12N15/67 , C07K2319/60 , C07K2319/61 , C07K2319/95 , C12N15/63 , C12Q1/6876 , C12Q1/6897
摘要： A fusion polypeptide comprising a protein of interest which has a reduced half-life of expression, and a nucleic acid molecule encoding the fusion polypeptide, are provided.

93. 发明公开

EP2114456A2 STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS 有权转让
标题翻译：稳定价格含水蛋白质组合物DESPLACEMENT缓冲区
公开(公告)号：EP2114456A2
公开(公告)日：2009-11-11
申请号：EP08700170.7
申请日：2008-01-11
申请人： Arecor Limited
发明人： JEZEK, Jan
IPC分类号： A61K47/18 , A61K47/14 , A61K47/22 , A61K38/44 , A61K38/27 , A61K39/29 , A61K9/08
CPC分类号： A61K39/292 , A61K38/21 , A61K38/27 , A61K38/28 , A61K38/36 , A61K38/44 , A61K38/443 , A61K39/12 , A61K39/39591 , A61K45/06 , A61K47/12 , A61K47/18 , A61K47/183 , A61K2039/55505 , A61K2039/55511 , C12N7/00 , C12N2730/10134 , C12Y101/03004 , C12Y107/03003 , C12Y111/01006 , Y02A50/39 , Y02A50/412 , Y02A50/464 , Y02A50/466
摘要： An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pKa that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pKa that is within 1 unit of the pH of step (a).

94. 发明公开

EP1499186A4 USE OF HEME OXYGENASE-1 AND PRODUCTS OF HEME DEGRADATION 审中-公开
标题翻译：使用血红素加氧酶1和血红素去除产品
公开(公告)号：EP1499186A4
公开(公告)日：2009-10-28
申请号：EP03746978
申请日：2003-04-15
申请人： BETH ISRAEL HOSPITAL
发明人： BACH FRITZ H , BERBERAT PASCAL O , ROBSON SIMON C
IPC分类号： A61K31/4015 , A61K31/4409 , A61K33/26 , A61K38/00 , A61K38/17 , A61K38/44 , A61P1/04 , A61P1/16 , A61P7/08 , A61P9/04 , A61P9/10 , A61P9/14 , A61P11/06 , A61P13/12 , A61P17/02 , A61P19/02 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/12 , A61P33/04 , A61P33/10 , A61P33/12 , A61P37/06 , A01N37/18 , C07K1/00 , G01N33/53
CPC分类号： A61K31/555 , A61K31/19 , A61K31/4025 , A61K31/409 , A61K31/455 , A61K33/00 , A61K33/26 , A61K38/1709 , A61K38/44 , C12Y114/99003 , A61K2300/00
摘要： The present invention relates to the treatment of disorders using heme oxygenase-1 and heme degradation products.

95. 发明公开

EP2095828A1 Use of S-adenosylmethionine (SAM) and superoxide dismutase (SOD) for the preparation of medicaments for the treatment of Alzeimer's disease 审中-公开
标题翻译：用于制备药物的用于治疗阿尔茨海默病的治疗中使用S-腺苷甲硫氨酸（SAM）和超氧化物歧化酶（SOD）的
公开(公告)号：EP2095828A1
公开(公告)日：2009-09-02
申请号：EP08425123.0
申请日：2008-02-29
申请人： Gnosis S.p.A.
发明人： Scarpa, Sigfrido , Fuso, Andrea , Damiani, Rosellina , Rossigni, Mauro
IPC分类号： A61K45/06 , A61K31/7076 , A61K38/44 , A61P25/28
CPC分类号： C12N9/0089 , A61K31/7076 , A61K38/446
摘要： The use of S-adenosylmethionine (SAM) in combination with superoxide dismutase (SOD) for the preparation of medicaments for the treatment of Alzheimer's disease.
摘要翻译：与超氧化物歧化酶（SOD）在制备药物中的阿尔茨海默氏病的治疗中联合使用S-腺苷甲硫氨酸（SAM）的。

96. 发明公开

EP1515753A4 PHARMACEUTICAL USE OF NITRIC OXIDE, HEME OXYGENASE-1 AND PRODUCTS OF HEME DEGRADATION 审中-公开
标题翻译：氮氧化物药物用途，血红素加氧酶1和血红素产品减
公开(公告)号：EP1515753A4
公开(公告)日：2009-07-15
申请号：EP03742119
申请日：2003-06-20
申请人： UNIV PITTSBURGH , BETH ISRAEL HOSPITAL
发明人： OTTERBEIN LEO E , BACH FRITZ H
IPC分类号： A61K38/00 , A61K31/4015 , A61K31/4025 , A61K31/409 , A61K31/4409 , A61K33/00 , A61K33/08 , A61K33/26 , A61K38/44 , A61K45/06 , A61P1/04 , A61P1/16 , A61P7/08 , A61P9/04 , A61P9/10 , A61P9/14 , A61P11/06 , A61P13/12 , A61P17/02 , A61P19/02 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/12 , A61P33/04 , A61P33/10 , A61P33/12 , A61P37/06 , A61P43/00 , A61K49/00
CPC分类号： A61K45/06 , A61K31/4025 , A61K31/409 , A61K33/00 , A61K33/26 , A61K2300/00

97. 发明公开

EP1655036A4 METHOD FOR TREATING ONCOLOGICAL DISEASES 失效转让
标题翻译： VERFAHREN ZUR BEHANDLUNG VON ONKOLOGISCHEN ERKRANKUNGEN
公开(公告)号：EP1655036A4
公开(公告)日：2009-06-17
申请号：EP04748955
申请日：2004-07-01
申请人： GENKIN DMITRY DMITRIEVICH , TETS VIKTOR VENIAMINOVICH
发明人： GENKIN DMITRY DMITRIEVICH , TETS VIKTOR VENIAMINOVICH , TETS GEORGY VIKTOROVICH
IPC分类号： A61K38/43 , A61K38/44 , A61K38/46 , A61K39/395 , A61P35/00
CPC分类号： A61K39/0011 , A61K38/465 , A61K38/48 , A61K2039/505 , A61K2039/53 , C07K16/44 , C12Y301/21001 , A61K2300/00
摘要： The invention relates to medicine and veterinary science and can be used for treating mainly solid tumors. The inventive method for treating oncological diseases consisting in injecting a blood extracellular DNA destroying agent into a systemic blood circulation. Said blood extracellular DNA destroying agent can be embodied in the form of a DNAse enzyme, in particular a bovine pancreatic DNAse which is parenterally injected in doses ranging from of 50 000 Kunz units to 250 000 000 Kunz units a day every day during 5-360 days or in the form of a recombinant human DNAse. In addition, a blood extracellular DNA binding agent embodied in the form of anti-DNA antibodies can be injected into a systemic blood circulation. In addition a modified agent which modifies the chemical composition and/or conformation and/or polymery and/or an association with proteins and/or lipids and/or ribonucleic acids of the blood extracellular DNA. Said modifying agent can be embodied in the form of a enzyme-ribonuclease. An extracellular ribonuclease of a Serratia Mercenses bacterium can be used in the form of said agents.
摘要翻译：本发明涉及医学和兽医学，可用于主要治疗实体瘤。本发明的治疗肿瘤疾病的方法包括将血细胞外DNA破坏剂注射到全身血液循环中。所述血细胞外DNA破坏剂可以以DNA酶的形式体现，特别是牛胰腺DNA酶，其在5-360天期间每天每天以50000Kunz单位至2500000000Kunz单位的剂量肠胃外注射天或以重组人DNAse的形式存在。此外，以抗DNA抗体形式体现的血细胞外DNA结合剂可以注射到全身血液循环中。另外还包括改变化学组成和/或构象和/或聚合和/或与血细胞外DNA的蛋白质和/或脂质和/或核糖核酸的缔合的修饰剂。所述修饰剂可以以酶 - 核糖核酸酶的形式体现。可以以所述药剂的形式使用粘质沙雷氏菌细菌的胞外核糖核酸酶。

98. 发明授权

EP1685254B1 ONCOLYTIC HERPES SIMPLEX VIRUS ENCODING A HETEROLOGOUS NITROREDUCTASE 有权转让
标题翻译：对于异源硝基还原酶编码溶瘤单纯疱疹病毒
公开(公告)号：EP1685254B1
公开(公告)日：2009-06-10
申请号：EP04798569.2
申请日：2004-11-17
申请人： Crusade Laboratories Limited
发明人： BROWN, Susanne,Moira, c/o Crusade Laboratories Ltd , DUNN,Paul, c/o Crusade Laboratories Limited
IPC分类号： C12N15/869 , A61K35/76 , C12N7/01 , C12N9/02 , A61K38/44 , A61K31/395
CPC分类号： C12N15/1135 , A01K2267/0331 , A61K35/13 , A61K48/00 , A61K2039/5256 , C12N7/00 , C12N15/86 , C12N2710/16643 , C12N2840/203 , Y02A50/473
摘要： An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.

99. 发明公开

EP2032156A2 COMPOSITIONS AND METHODS FOR THE DELIVERY OF OXYGEN 有权
标题翻译：用于输送氧的组合物和方法
公开(公告)号：EP2032156A2
公开(公告)日：2009-03-11
申请号：EP07795174.7
申请日：2007-05-21
申请人： The Regents of the University of California
发明人： CARY, Stephen, P.L. , BOON, Elizabeth, M. , WEINERT, Emily , WINGER, Jonathan, A. , MARLETTA, Michael, A.
IPC分类号： A61K38/44
CPC分类号： C07K14/47 , A61K38/00 , C07K14/195 , C07K14/33 , C07K14/435 , C07K14/43545 , C07K14/43563 , C07K14/43581 , Y02A50/469 , Y02A50/471 , Y02A50/478 , Y10T436/102499
摘要： H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O 2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O 2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O 2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O 2 is beneficial.
摘要翻译： H-NOX蛋白被突变以表现出改善的或最佳的血液O2输送的动力学和热力学性质。工程化的H-NOX蛋白质包含相对于相应的野生型H-NOX结构域赋予改变的O 2或NO配体结合的突变，并且作为生理上相容的哺乳动物血液O 2气体载体起作用。本发明还提供了使用野生型或突变型H-NOX蛋白治疗O2递送有益的任何病症的药物组合物，试剂盒和方法。

100. 发明公开

EP2031054A1 Fusion protein, gene related to fusion protein, vector, transformants, and anti-inflammatory medicinal composition 审中-公开
标题翻译：融合蛋白，与融合蛋白相关基因，载体，转化体，和抗炎药物组合物
公开(公告)号：EP2031054A1
公开(公告)日：2009-03-04
申请号：EP08014909.9
申请日：2008-08-22
申请人： Nipro Corporation
发明人： Otagiri, Masaki , Ikuta, Shotaro
IPC分类号： C12N9/02 , C12N15/62 , A61K38/44
CPC分类号： C12N15/62 , A61K38/00 , C07K2319/35 , C12N9/0036
摘要： Fusion protein comprises a thioredoxin and human serum albumin. The thioredoxin comprises a protein comprising the amino acid sequence shown in SEQ. ID. No.1, or the like, the human serum albumin comprises a protein comprising the amino acid sequence shown in SEQ. ID. No. 2, or the like. The fusion protein of the invention allows the activity of thioredoxin to be maintained over a long period of time. It is thus possible to provide a protein preparation that is stable over long periods of time.
摘要翻译：融合蛋白包含硫氧还蛋白和人血清白蛋白。硫氧还蛋白包含含有SEQ中所示的氨基酸序列的蛋白质。 ID。 1号，或类似的人血清白蛋白包括包含在SEQ所示的氨基酸序列的蛋白质。 ID。号 2，或类似物。本发明的融合蛋白硫氧还蛋白允许的活性维持在一段长的时间。有可能因此提供蛋白质制剂确实是在很长一段时间保持稳定。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式